Project Grant R01AT013263
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of Pennsylvania $137,894 on May 9, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the cortical mechanisms of psilocybin in treating chronic pain. The research project, with a completion date of December 31, 2025, addresses a critical public health need arising from the opioid crisis and closure of...
- Federal Grant Award Summary New York University School of Medicine received a $871,225 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), effective March 1, 2026, through November 30, 2030. The award supports a clinical research trial investigating psilocybin as a novel therapeutic intervention for residual anhedonia (loss of interest or pleasure in previously rewarding activities) in individuals currently taking...
- Federal Grant Award Summary The University of California, San Diego received a $439,500 Project Grant from the National Center for Complementary and Integrative Health under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) for the period April 1, 2026 through March 31, 2028. The award supports the development of advanced technologies and methodologies to enable high-resolution structural analysis of native polyketide synthase (PKS) megasynthases using...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Regents of the University of California, San Francisco a $1,179,715 Project Grant on March 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This research initiative, scheduled for completion by January 31, 2034, focuses on elucidating the fundamental mechanisms underlying nociception—the process by which nerve fibers...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Medical University of South Carolina a Project Grant totaling $187,984 under the Drug Use and Addiction Research Programs (CFDA 93.279) on October 10, 2025, with a completion date of April 30, 2028. This award supports research investigating the therapeutic potential of psilocybin in addressing stress-cued reinstatement and relapse behavior in opioid use disorder (OUD) patients, with particular focus on...
- Federal Project Grant Award Summary Princeton University received a $246,000 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded June 15, 2025, with completion targeted for May 31, 2027. The grant supports fundamental neuroscience research investigating the systems-level brain mechanisms underlying psilocybin's therapeutic potential for treating anxiety, depression, addiction, pain, and illness-associated...
- Federal Cooperative Agreement Summary The National Center for Complementary and Integrative Health (NCCIH) awarded a Cooperative Agreement valued at $200,000 to the University of Colorado-Denver on August 15, 2025, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). This award supports the INSPIRE Network (Innovation in Science of Psychedelics with Inclusive Research in Elders), a geographically diverse, transdisciplinary research consortium designed to...
- Federal Grant Award Summary The National Center for Complementary and Integrative Health (NCCIH) awarded The Pennsylvania State University a $108,426 Project Grant effective October 3, 2025, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) to investigate ghost pipe (Monotropa uniflora) as a source of novel analgesic compounds. The research will deliver comprehensive pharmacognosy and analgesic screening capabilities to identify bioactive compounds...
- Federal Project Grant Award Summary The University of California, San Francisco received a $601,259 Project Grant from the National Center for Complementary and Integrative Health (NCCIH) under the Research and Training in Complementary and Integrative Health program (CFDA 93.213), awarded April 17, 2026, with completion targeted for March 31, 2029. This research initiative will assess the multi-site feasibility of an integrated treatment combining whole-body hyperthermia (WBH) and cognitive...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a Project Grant award of $736,713 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective February 15, 2026, with an ultimate completion date of November 30, 2030. The grant funds the Psilocybin Research and Implementation Study for Mental Health and Substance Use (PRISM), a longitudinal research study designed to assess the real-world safety and...
The University of California, San Diego received a $788,967 Project Grant award dated April 16, 2026, from the National Center for Complementary and Integrative Health (NCCIH) under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). This five-year research initiative, extending through March 31, 2031, will investigate the effects and mechanisms by which psilocybin induces pain relief in patients with chronic phantom limb pain (CPLP). The research addresses a significant clinical need, as CPLP affects approximately 64% of the estimated 356 million people worldwide with amputations and remains largely treatment-resistant to conventional therapies. The project will advance understanding of psilocybin's analgesic mechanisms through mechanistic research focused on the default mode network (DMN), a midline cortical neural network implicated in both chronic pain perception and psilocybin's neurobiological effects. Building upon preliminary clinical trial findings demonstrating the safety and feasibility of 25 milligrams of psilocybin for CPLP treatment, this funded research will generate evidence-based knowledge regarding if and how psilocybin modulates chronic pain through neural pathways, potentially supporting the development of durable pain management interventions that address both nociceptive and affective dimensions of chronic pain conditions.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $789.0k | 4/16/26 |